Macquarie sees revenue lift for Australia's Integral Diagnostics on MRI and CT tailwinds

Integral Diagnostics

01/12/2025 22:55

** Macquarie sees multiple revenue catalysts for Integral Diagnostics IDX.AX over the next 12 months, citing magnetic resonance imaging deregulation and a computed tomography boost from the lung-screening rollout

** EBITDA margin expected to edge higher, with most gains likely in 2H26, lifting the second-half estimate to 53% from 51%

** Also sees near-term tailwinds bolstering both revenue and margins

** Stock down 11.7% YTD as of last close

(Reporting by Kumar Tanishk in Bengaluru)

((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk http://www.x.com/thatstanishk))